Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11136058 | 0.78 | — | — | |
| SCHEMBL7051925 | 0.78 | — | — | |
| SCHEMBL777742 | 0.76 | CA1 (0.35) | CA1CA2CA7CA9CA13 | |
| SCHEMBL7054561 | 0.76 | CES1 (0.32) | CES1 | |
| SCHEMBL776785 | 0.76 | CES1 (0.32) | CES1 | |
| SCHEMBL11897704 | 0.74 | CES1 (0.44) | CES1 | |
| SCHEMBL21799432 | 0.74 | CES1 (0.31) | CES1 | |
| SCHEMBL11929447 | 0.74 | LMNA (0.38) | CES1CA1CA2CA7CA9 | |
| SCHEMBL10786838 | 0.74 | NOS2 (0.32) | CES1ATR | |
| SCHEMBL12833421 | 0.74 | CES1 (0.31) | CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207286-A1 | CONJUGATES OF A CHOLINESTERASE MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2018-07-26 | — | — | US | disclosed |
| US-20180085468-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2018-03-29 | — | — | US | disclosed |
| US-9763995-B2 | Polymer conjugates of protegrin peptides | NEKTAR THERAPEUTICS (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-9636412-B2 | Conjugates of an anti-TNF-alpha antibody | NEKTAR THERAPEUTICS (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-9421275-B2 | Oligomer-calcimimetic conjugates and related compunds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160158311-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | NEKTAR THERAPEUTICS | 2016-06-09 | — | — | US | disclosed |
| US-20110171165-A1 | POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES | NEKTAR THERAPEUTICS | 2011-07-14 | — | — | US | disclosed |
| US-20110171160-A1 | POLYMER CONJUGATES OF KISS1 PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165113-A1 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110135623-A1 | Conjugates of a Cholinesterase Moiety and a Polymer | NEKTAR THERAPEUTICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| EP-0882715-B1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA CHEMICAL IND CO LTD (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6339045-B1 | CAN BE USED IN A SMALL AMOUNT, SHOWING A GOOD SELECTIVITY BETWEEN CROP AND WEED, AND CAUSING NO PHYTOTOXICITY | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171160-A1 | POLYMER CONJUGATES OF KISS1 PEPTIDES | KISS1R, PROKR1, NGLY1 | CES1 2573/4885ATR 4407/4885CA12 1255/4885 |
| US-20110135623-A1 | Conjugates of a Cholinesterase Moiety and a Polymer | BCHE, ACHE, DNPEP | CES1 9/4885ATR 3810/4885CA12 57/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | CES1 2418/4885ATR 4166/4885CA12 574/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | CES1 700/4885ATR 3936/4885CA12 930/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | CES1 670/4885ATR 3944/4885CA12 842/4885 |
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NGLY1, IAPP, NPSR1 | CES1 2324/4885ATR 4413/4885CA12 1622/4885 |
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | IAPP, GCG, INSR | CES1 1247/4885ATR 4690/4885CA12 398/4885 |
| US-20160158311-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | PSMG3, PSMB11, UBQLN1 | CES1 4422/4885ATR 4139/4885CA12 3608/4885 |
| US-20180085468-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | IL2, IL2RA, ILF2 | CES1 3073/4885ATR 4853/4885CA12 895/4885 |
| US-20180207286-A1 | CONJUGATES OF A CHOLINESTERASE MOIETY AND A POLYMER | BCHE, ACHE, DNPEP | CES1 8/4885ATR 3830/4885CA12 62/4885 |
| US-20110165113-A1 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES | NGLY1, VIP, DNPEP | CES1 3736/4885ATR 4631/4885CA12 991/4885 |
| US-20110171165-A1 | POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES | OGFR, OGFRL1, OPRL1 | CES1 4116/4885ATR 4806/4885CA12 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.